Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Bachem Holding AG (BANB.SW)
CHF74.00
-1.40 (-1.86%)
CH SIX Healthcare Drug Manufacturers - Specialty & Generic
Address
Hauptstrasse 144 4416
Bubendorf, CH
Bubendorf, CH
CEO
Anne-Kathrin Stoller
Website
bachem.com
IPO
1998-07-17
ISIN CH1176493729
Also trades on
London Stock Exchange · 0QND.L (CHF)
Other OTC · BCHMF (USD)
Swiss Exchange · BANB.SW (CHF)
Description
Bachem Holding AG serves pharmaceutical and biotechnology companies globally, providing products crucial for research, clinical development, and commercial use. The company's primary focus is on the design, manufacturing, and regulatory support for peptide active pharmaceutical ingredients (APIs), specifically targeting novel peptide and oligonucleotide chemical entities (NCEs). Additionally, Bachem offers commercially available NCEs and generic compounds. Its comprehensive service portfolio includes project management, quality assurance and regulatory guidance, analytical testing, production adhering to Good Manufacturing Practices (GMP), manufacturing for research purposes, and expertise in supply chain and vertical integration. Established in 1971, Bachem Holding AG is headquartered in Bubendorf, Switzerland, and functions as a subsidiary of Ingro Finanz AG.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
CHF74.00
-1.40 (-1.86%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
149.4K
Beta
0.81
Float Shares
30.99M
Free Float %
41.4%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -5.12% | -2.47% | +8.55% | +29.38% | +48.22% | +31.48% | +48.79% | -19.44% | -22.14% | +419.26% | +230.54% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
74.00
Ratings Trend (MoM)
60% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 2 | 0 |
| Buy | 4 | 0 |
| Hold | 3 | 0 |
| Sell | 1 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
7.40
Safe zone
Piotroski F-Score
5 / 9
Average
MOAT Score
4 / 10
Developing
Composite Rating
B
Overall Score
3 / 5
Medium
DCF Score
1 / 5
Low
ROE Score
4 / 5
High
ROA Score
5 / 5
High
D/E Score
3 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
2 / 5
Medium
Operational MOAT
✗ Below peers
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%+14.8% ★ Q4'25: +13.2% (vs Q4'23)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%+23.8% ★ Q4'25: +28.2% (vs Q4'23)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%+31.1% ★ Q4'25: +2.3% (vs Q4'23)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%+21.6% ★ Q4'25: +22.0% (vs Q4'23)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%+9.6% ★ Q4'25: +22.3% (vs Q4'23)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%0.0% ★ Q4'25: 0.0% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×0.30× Q4'25: 0.13× (vs Q4'23)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2011 actual |
Dec 2012 actual |
Dec 2013 actual |
Dec 2014 actual |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 6 Rev. Ana. 7 EPS Ana. |
Dec 2027 8 Rev. Ana. 9 EPS Ana. |
Dec 2028 8 Rev. Ana. 6 EPS Ana. |
Dec 2029 7 Rev. Ana. 4 EPS Ana. |
Dec 2030 7 Rev. Ana. 2 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
145.81M
est: 147.60M (-1.2%)
|
157.30M
est: 157.61M (-0.2%)
|
170.69M
est: 171.00M (-0.2%)
|
183.94M
est: 185.64M (-0.9%)
|
208.60M
est: 201.28M (+3.6%)
|
236.48M
est: 238.00M (-0.6%)
|
261.61M
est: 262.00M (-0.1%)
|
282.50M
est: 277.31M (+1.9%)
|
313.72M
est: 310.52M (+1.0%)
|
402.00M
est: 386.69M (+4.0%)
|
503.23M
est: 523.25M (-3.8%)
|
531.74M
est: 534.74M (-0.6%)
|
577.32M
est: 577.77M (-0.1%)
|
605.26M
est: 609.91M (-0.8%)
|
695.07M
est: 684.68M (+1.5%)
|
951.50M
939.96M – 962.32M
+39.0% YoY
|
1.16B
1.11B – 1.24B
+22.1% YoY
|
1.36B
1.36B – 1.36B
+17.0% YoY
|
1.50B
1.46B – 1.56B
+10.5% YoY
|
1.78B
1.73B – 1.86B
+18.8% YoY
|
| EBITDA |
32.79M
est: 44.10M (-25.6%)
|
42.52M
est: 29.83M (+42.5%)
|
47.60M
est: 42.43M (+12.2%)
|
51.73M
est: 50.29M (+2.9%)
|
56.28M
est: 60.89M (-7.6%)
|
65.96M
est: 63.88M (+3.2%)
|
69.74M
est: 74.05M (-5.8%)
|
78.32M
est: 82.97M (-5.6%)
|
87.25M
est: 88.09M (-1.0%)
|
122.58M
est: 95.86M (+27.9%)
|
156.47M
est: 108.52M (+44.2%)
|
160.54M
est: 125.14M (+28.3%)
|
163.28M
est: 169.19M (-3.5%)
|
178.76M
est: 179.47M (-0.4%)
|
189.88M
est: 200.50M (-5.3%)
|
278.63M
275.26M – 281.80M
+39.0% YoY
|
340.16M
325.10M – 362.41M
+22.1% YoY
|
397.95M
397.36M – 398.55M
+17.0% YoY
|
439.58M
426.51M – 457.58M
+10.5% YoY
|
522.33M
506.80M – 543.72M
+18.8% YoY
|
| EBIT |
12.86M
est: 14.15M (-9.1%)
|
20.20M
est: 15.91M (+27.0%)
|
29.45M
est: 23.87M (+23.4%)
|
33.87M
est: 32.03M (+5.8%)
|
38.50M
est: 39.48M (-2.5%)
|
45.06M
est: 45.09M (-0.1%)
|
48.67M
est: 50.10M (-2.9%)
|
54.81M
est: 65.56M (-16.4%)
|
62.36M
est: 59.60M (+4.6%)
|
96.66M
est: 71.72M (+34.8%)
|
131.75M
est: 81.19M (+62.3%)
|
127.22M
est: 93.63M (+35.9%)
|
129.38M
est: 133.80M (-3.3%)
|
135.26M
est: 141.93M (-4.7%)
|
150.29M
est: 158.56M (-5.2%)
|
220.35M
217.67M – 222.85M
+39.0% YoY
|
269.00M
257.09M – 286.59M
+22.1% YoY
|
314.70M
314.23M – 315.17M
+17.0% YoY
|
347.63M
337.29M – 361.86M
+10.5% YoY
|
413.07M
400.79M – 429.98M
+18.8% YoY
|
| Net Income |
9.41M
est: 25.50M (-63.1%)
|
15.30M
est: 10.04M (+52.4%)
|
23.60M
est: 16.60M (+42.2%)
|
29.07M
est: 25.62M (+13.4%)
|
31.84M
est: 31.99M (-0.5%)
|
41.21M
est: 37.29M (+10.5%)
|
41.77M
est: 45.82M (-8.8%)
|
46.64M
est: 50.06M (-6.8%)
|
54.16M
est: 54.51M (-0.6%)
|
78.06M
est: 62.30M (+25.3%)
|
114.68M
est: 70.52M (+62.6%)
|
100.68M
est: 98.52M (+2.2%)
|
111.86M
est: 113.57M (-1.5%)
|
120.25M
est: 134.19M (-10.4%)
|
148.79M
est: 115.54M (+28.8%)
|
186.20M
173.77M – 194.94M
+61.2% YoY
|
226.84M
188.12M – 244.42M
+21.8% YoY
|
260.19M
224.59M – 286.77M
+14.7% YoY
|
292.97M
281.65M – 308.57M
+12.6% YoY
|
351.95M
338.34M – 370.68M
+20.1% YoY
|
| SGA |
27.15M
est: 27.57M (-1.5%)
|
27.64M
est: 29.04M (-4.8%)
|
28.56M
est: 29.95M (-4.6%)
|
27.66M
est: 31.05M (-10.9%)
|
30.86M
est: 30.45M (+1.4%)
|
31.74M
est: 36.15M (-12.2%)
|
31.99M
est: 35.30M (-9.4%)
|
27.83M
est: 19.13M (+45.5%)
|
29.38M
est: 41.99M (-30.0%)
|
30.17M
est: 33.79M (-10.7%)
|
34.87M
est: 38.25M (-8.8%)
|
37.76M
est: 44.11M (-14.4%)
|
37.36M
est: 37.70M (-0.9%)
|
39.23M
est: 39.99M (-1.9%)
|
39.22M
est: 44.68M (-12.2%)
|
62.09M
61.34M – 62.79M
+39.0% YoY
|
75.80M
72.44M – 80.76M
+22.1% YoY
|
88.68M
88.54M – 88.81M
+17.0% YoY
|
97.95M
95.04M – 101.96M
+10.5% YoY
|
116.39M
112.93M – 121.16M
+18.8% YoY
|
| EPS |
0.14
est: 0.88 (-84.0%)
|
0.23
est: 1.20 (-80.9%)
|
0.35
est: 1.56 (-77.5%)
|
0.43
est: 1.99 (-78.4%)
|
0.47
est: 0.48 (-2.9%)
|
0.61
est: 0.59 (+2.7%)
|
0.62
est: 0.66 (-6.3%)
|
0.69
est: 0.67 (+3.3%)
|
0.78
est: 0.77 (+0.8%)
|
1.12
est: 1.04 (+7.8%)
|
1.62
est: 1.58 (+2.4%)
|
1.37
est: 1.42 (-3.8%)
|
1.50
est: 1.52 (-1.1%)
|
1.60
est: 1.58 (+1.1%)
|
1.98
est: 1.56 (+26.7%)
|
2.41
2.32 – 2.60
+54.2% YoY
|
3.01
2.51 – 3.26
+24.9% YoY
|
3.47
3.00 – 3.83
+15.3% YoY
|
3.91
3.76 – 4.12
+12.6% YoY
|
4.70
4.51 – 4.94
+20.1% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | B | 3/5 | 1/5 | 4/5 | 5/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-28 | B | 3/5 | 1/5 | 4/5 | 5/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-27 | B | 3/5 | 1/5 | 4/5 | 5/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-26 | B | 3/5 | 1/5 | 4/5 | 5/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-22 | B | 3/5 | 1/5 | 4/5 | 5/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-21 | B | 3/5 | 1/5 | 4/5 | 5/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-20 | B | 3/5 | 1/5 | 4/5 | 5/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-19 | B | 3/5 | 1/5 | 4/5 | 5/5 | 3/5 | 2/5 | 2/5 |
| 2026-05-18 | B | 3/5 | 1/5 | 4/5 | 5/5 | 3/5 | 2/5 | 2/5 |
| 2026-05-15 | B | 3/5 | 1/5 | 4/5 | 5/5 | 3/5 | 2/5 | 2/5 |
| 2026-05-13 | B | 3/5 | 1/5 | 4/5 | 5/5 | 3/5 | 2/5 | 2/5 |
| 2026-05-12 | B | 3/5 | 1/5 | 4/5 | 5/5 | 3/5 | 2/5 | 2/5 |
| 2026-05-11 | B | 3/5 | 1/5 | 4/5 | 5/5 | 3/5 | 2/5 | 2/5 |
| 2026-05-08 | B | 3/5 | 1/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-07 | B | 3/5 | 1/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-06 | B | 3/5 | 1/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-05 | B | 3/5 | 1/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-04 | B | 3/5 | 1/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-04-30 | B | 3/5 | 1/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-04-29 | B | 3/5 | 1/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-04-28 | B | 3/5 | 1/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-04-27 | B | 3/5 | 1/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-04-24 | B | 3/5 | 1/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-04-23 | B- | 3/5 | 1/5 | 4/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-22 | B- | 3/5 | 1/5 | 4/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-21 | B- | 3/5 | 1/5 | 4/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-20 | B- | 3/5 | 1/5 | 4/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-17 | B- | 3/5 | 1/5 | 4/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-16 | B- | 3/5 | 1/5 | 4/5 | 5/5 | 1/5 | 2/5 | 2/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
72.33M
OE per share TTM
0.97
Owner's Yield
1.26%
Maintenance CapEx ratio
118.19%
Maint CapEx / Avg PPE
135.0%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
Held by 100 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | abrdn International Small Cap Active ETF ASCI | 0.96% | 755.8K | 1.05% |
| 2 | iShares Healthcare Innovation UCITS ETF HEAL.L | 0.32% | 3.70M | 0.40% |
| 3 | Amundi MSCI Europe Small Cap ESG Broad Transition UCITS ETF Dist X026.DE | 0.27% | 938.3K | 0.23% |
| 4 | Amundi MSCI Europe Small Cap ESG Broad Transition UCITS ETF Acc CEM.PA | 0.27% | 938.3K | 0.23% |
| 5 | iShares MSCI Europe Small-Cap ETF IEUS | 0.19% | 337.5K | 0.41% |
| 6 | Xtrackers MSCI Europe Small Cap UCITS ETF 1C XXSC.L | 0.19% | 6.34M | 0.30% |
| 7 | Franklin FTSE Switzerland ETF FLSW | 0.16% | 132.2K | 0.09% |
| 8 | iShares Core SPI(R) ETF (CH) CHSPI.SW | 0.12% | 8.63M | 0.10% |
| 9 | WisdomTree International Equity Fund DWM | 0.10% | 670.1K | 0.48% |
| 10 | iShares Currency Hedged MSCI EAFE Small-Cap ETF HSCZ | 0.08% | 191.2K | 0.83% |
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
68.1K
Shares Outstanding
74.94M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Achim Pluckebaum | Chief Information Officer | — | male |
| Alain Schaffter | Chief Financial Officer | — | male |
| Anne-Kathrin Stoller | Chief Executive Officer | — | — |
| Barbora Blaha | Head of Investor Relations | — | female |
| Daniel Grotzky | Head of Group Communications | — | — |
| Gunther Loidl | Chief Technology Officer | — | — |
| Hans van Hees | Chief Operations Officer | — | male |
| Michael Suter | Vice President of Global Accounting | — | male |
| Torsten Wohr | Chief Commercial Officer | — | — |
| Viviane Minden | Chief Human Resources Officer | — | — |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for BANB.SW
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
